荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 05-22 16:08:22

84.800

-1.450

-1.68%

最高87.700	最低83.650	成交量241.66万
今开87.700	昨收86.250	日振幅4.70%
总市值477.94亿	流通市值176.88亿	总股本5.64亿
成交额2.05亿	换手率1.16%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":84.8,"timestamp":1779437302009,"preClose":86.25,"halted":0,"volume":2416637,"delay":0,"changeRate":-0.016811594202898583,"floatShares":208581239,"shares":563608243,"eps":1.4867603018264735,"marketStatus":"休市中","change":-1.45,"latestTime":"05-22 16:08:22","open":87.7,"high":87.7,"low":83.65,"amount":205299051,"amplitude":0.046957,"askPrice":84.8,"askSize":3500,"bidPrice":84.75,"bidSize":500,"shortable":3,"etf":0,"ttmEps":2.6904575775683073,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":86.25,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":0.6721631372661475,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":116.7,"timestamp":1779433200000,"preClose":121.99,"halted":0,"volume":12342600,"delay":0,"premium":"-36.95"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2637831217","title":"汇添富基金减持荣昌生物(09995)16万股 每股作价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637831217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637831217?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:49","pubTimestamp":1779454173,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，汇添富基金减持荣昌生物(09995)16万股，每股作价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","BK1161","LU1064130708.USD","LU2488822045.USD","688331","EWH","LU2328871848.SGD","BK1574","BK1583","BK0239","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151063469","title":"异动解读｜荣昌生物盘中上涨3.55%，生物科技板块集体反弹叠加基本面利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1151063469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151063469?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:51","pubTimestamp":1779328314,"startTime":"0","endTime":"0","summary":"5月21日，荣昌生物盘中上涨3.55%，报88.25港元，成交额1.09亿港元。消息面上，生物科技板块整体走强，康方生物涨6.96%、科伦博泰生物涨3.52%、信达生物涨3.09%，板块联动效应显著。基本面方面，公司董事长近日表示泰它西普凭借FDA孤儿药资格认定，几乎不受美国集采降价政策影响，海外临床与FDA沟通顺利；一季度营收6.56亿元同比增长24.76%，归母净利润3.28亿元成功扭亏，9家机构给出买入评级，目标均价150.8元，多重利好共振推动股价修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881660","title":"荣昌生物董事长王威东：国内销售、海外授权双向赋能丨21健谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881660","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636881660?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:46","pubTimestamp":1779259586,"startTime":"0","endTime":"0","summary":"2026年一季度创新药企业绩成绩单出炉，荣昌生物（688331.SH/9995.HK）经营成效显著。数据显示，报告期内荣昌生物营收6.56亿元，同比增长24.76%，归母净利润3.28亿元，较上年同期成功扭亏为盈。对于创业十八年的老牌企业荣昌生物而言，盈利意味着战略姿态的主动化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743371973.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743371973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","LU2328871848.SGD","BK1161","LU1064130708.USD","BK1574","LU2488822045.USD","LU1969619763.USD","09995","LU1064131003.USD","LU2148510915.USD","BK1583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242057","title":"荣昌生物再斥0.35亿元购买华泰证券理财，12个月内累计投向4.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242057","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168242057?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:21","pubTimestamp":1779189711,"startTime":"0","endTime":"0","summary":"荣昌生物5月19日公告，再度动用闲置自有资金0.35亿元，与华泰证券签订两份新理财协议。至此，公司在12个月内累计向同一机构认购理财金额达4.88亿元，占此前董事会批准的25亿元现金管理额度的19.52%。\\n\\n此前5月14日，荣昌生物已通过华泰证券认购四款理财产品，合计4.53亿元。本次新增0.35亿元后，公司与华泰证券的六笔理财协议因在12个月内与同一金融机构办理且性质相似，需合并计算。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853600","title":"荣昌生物(09995)进一步购买3500万元的华泰证券理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853600","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636853600?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:20","pubTimestamp":1779189643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)公布，于2026年5月19日，公司进一步与华泰证券订立(1)华泰证券理财产品5号协议，据此公司同意以人民币1500万元的闲置自有资金向华泰证券购买理财产品;及(2)华泰证券理财产品6号协议，据此公司同意以人民币2000万元的闲置自有资金向华泰证券购买理财产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1781817850.SGD","LU1064131003.USD","LU1328615791.USD","BK1583","LU1580142542.USD","LU2488822045.USD","BK0276","LU0164865239.USD","LU1934453819.USD","LU1979443071.USD","BK1574","BK0188","LU1808992512.USD","LU2328871848.SGD","09995","BK0183","BK0028","BK0012","LU0039217434.USD","LU1064130708.USD","LU2148510915.USD","688331","BK0239","LU1969619763.USD","601688","LU0871576103.HKD","LU0531971595.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU0315179316.USD","AIPO","06978","IE00B031HY20.USD","AGIX","LU1226287792.SGD","LU1152091168.USD","LU0348827113.USD","CHAT","LU0456846285.SGD","02269","LU2097828631.EUR","BK1161","02616","09688","09995","IE00BPRC5H50.USD","LU1719994722.HKD","01801","LU0572944931.SGD","BK1588","01177","LU0067412154.USD","06185","LU1960683339.HKD","ARTY","LU0634319403.HKD","09926","LU1303224171.USD","LU1880383366.USD","LU0348767384.USD","01093","159992","LU0140636845.USD","LU1993786604.SGD","LU0856984785.SGD","01877","BK1589","LU0561508036.HKD","06160","LU0516422952.EUR","LU0326950275.SGD","LU0456827905.SGD","SG9999002562.SGD","02142","BK1583","LU1152091754.HKD","LU1226288170.HKD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636073722","title":"荣昌生物：变更部分募投项目并调整金额 新增RC148子项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073722","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636073722?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:07","pubTimestamp":1779106020,"startTime":"0","endTime":"0","summary":"5月18日，荣昌生物（688331/09995）发布公告，为提高募集资金使用效率，公司决定对“抗肿瘤抗体新药研发项目”中的部分临床试验子项目进行调整。本次变更的主要内容包括新增子项目RC148，并将RC88、RC108及RC118子项目的剩余募集资金调减，募集资金投资总金额保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740712037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU2328871848.SGD","LU2148510915.USD","LU1969619763.USD","LU1064130708.USD","BK1583","BK1161","688331","BK0239","BK1574","LU1064131003.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073703","title":"荣昌生物：开展董事会换届选举 公布候选人名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073703","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636073703?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:07","pubTimestamp":1779106020,"startTime":"0","endTime":"0","summary":"荣昌生物（688331/09995）发布公告，根据相关法律法规，公司于2026年5月18日召开第二届董事会第三十八次会议，审议通过了关于董事会换届选举的议案。经公司董事会提名委员会对第三届董事会董事候选人任职资格的审查，提名王威东、房健民、温庆凯、王荔强、房艺为非独立董事候选人，提名宋希亮、黄国滨、陈云金为独立董事候选人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740711871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","LU2488822045.USD","LU2148510915.USD","BK1574","09995","LU1969619763.USD","BK1583","LU1064131003.USD","LU1064130708.USD","LU2328871848.SGD","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","LU0348766576.USD","IE00BPRC5H50.USD","06855","LU0348767384.USD","LU0348827113.USD","159938","LU0417516738.SGD","02410","LU0348825331.USD","159992","02162","IE00B5MMRT66.SGD","LU0348784397.USD","LU2488822045.USD","LU0634319403.HKD","LU2399975544.HKD","BK1583","BK1600","BK1574","09995","BK1593","02268","BK1515","06978","LU2328871848.SGD","LU1794554557.SGD","LU0348735423.USD","01672","09926","LU0348783233.USD","LU2476274308.USD","LU1720050803.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0417516571.SGD","LU1969619763.USD","SG9999014674.SGD","LU2476274720.SGD","BK1161","00460","BK1141","LU0540923850.HKD","09939","LU2778985437.USD","LU0561508036.HKD","LU0417516902.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","IE00B5MMRT66.SGD","LU1152091168.USD","SG9999002562.SGD","BK1574","LU1688375341.USD","LU0039217434.USD","01801","06185","09688","LU0326950275.SGD","01877","09995","02616","IE00BZ08YS42.EUR","BK1161","01093","LU0417516738.SGD","LU1242518857.USD","LU1242518931.SGD","LU0561508036.HKD","159992","LU0588546209.SGD","LU2097828631.EUR","BK1141","LU1152091754.HKD","LU1993786604.SGD","LU0456827905.SGD","601066","LU0979878070.USD","BK1588","LU2399975544.HKD","LU0516422952.EUR","06160","LU2097828474.EUR","IE00BZ08YT58.USD","IE00B543WZ88.USD","02142","IE00B0JY6N72.USD","LU0359202008.SGD","02269","LU1226287875.USD","06978","09926","IE00BZ08YR35.GBP","LU0516423174.USD","LU1969619763.USD","LU2097828557.USD","LU1303224171.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088673","title":"荣昌生物：5月11日召开业绩说明会，《十五五·科创惠民--科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明》、《\"对话成长\"2025年度暨2026年一季度集体业绩说明会》参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635088673?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:03","pubTimestamp":1778839422,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月15日荣昌生物发布公告称公司于2026年5月11日召开业绩说明会，《十五五·科创惠民--科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明》、《\"对话成长\"2025年度暨2026年一季度集体业绩说明会》参与。泰它西普治疗重症肌无力适应症已于2025年12月成功纳入国家医保目录，目前按医保支付标准执行。公司目前生产经营活动正常，不存在应披露而未披露的重大","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU2148510915.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","09995","BK1574","BK1583","159982","LU1064131003.USD","BK0239","688331","LU1969619763.USD","LU1064130708.USD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088379","title":"荣昌生物（688331）披露使用7000万美元闲置自有资金购买结构性存款产品公告，5月15日股价下跌0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088379","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635088379?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:54","pubTimestamp":1778838887,"startTime":"0","endTime":"0","summary":"近日，荣昌生物制药(烟台)股份有限公司与华侨银行订立理财产品协议，使用美元70.0百万元的闲置自有资金购买收益联结型结构性存款产品，产品起始日为2026年5月21日，到期日为2027年5月19日，预期年化收益率随市场波动。该交易构成联交所上市规则下的须予披露交易，已获董事会批准，交易条款公平合理，符合公司及股东整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260515/32228130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688331","LU2148510915.USD","BK1583","BK0239","09995","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD","BK1574","LU1969619763.USD","BK1161","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722376","title":"荣昌生物(09995)购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722376","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635722376?lang=zh_cn&edition=full","pubTime":"2026-05-15 07:04","pubTimestamp":1778799869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，2026年5月14日，公司与华泰证券订立(1)华泰证券理财产品1号协议，据此公司同意以人民币6000万元的闲置自有资金向华泰证券购买理财产品;(2)华泰证券理财产品2号协议，据此公司同意以人民币7500万元的闲置自有资金向华泰证券购买理财产品;(3)华泰证券理财产品3号协议，据此本公司同意以人民币1.02亿元的闲置自有资金向华泰证券购买理财产品及(4)华泰证券理财产品4号协议，据此公司同意以人民币2.16亿元的闲置自有资金向华泰证券购买理财产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","LU2148510915.USD","BK1583","BK0239","09995","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD","BK1574","LU1969619763.USD","BK1161","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141438080","title":"荣昌生物斥资0.70亿美元购入华侨银行中风险结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=1141438080","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141438080?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:41","pubTimestamp":1778748104,"startTime":"0","endTime":"0","summary":"荣昌生物5月14日披露，其与华侨银行签署结构性存款协议，使用7000万美元闲置自有资金购买“华侨银行有限公司收益联结型结构性存款『增利』系列”产品。\\n\\n此次交易基于公司董事会2026年3月27日通过的决议——批准使用不超过25亿元人民币的闲置自有资金进行现金管理。\\n\\n公司表示，通过投资该类中低风险、收益高于同期定存的产品，可提高闲置资金使用效率；并称已对交易条款进行公平磋商，认为本次投资符合全体股东整体利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866917","title":"荣昌生物(09995)近期合共购买14.3亿元的银行理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635866917?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:57","pubTimestamp":1778669853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 公布，于2026年4月28日，公司与浦发银行烟台分行订立浦发银行理财产品1号协议及浦发银行理财产品2号协议，据此公司同意分别以人民币2.2亿元及8000万元的闲置自有资金向浦发银行烟台分行购买理财产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","BK0239","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","09995","BK1161","BK1574","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","161121","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166498885","title":"异动解读 | 荣昌生物盘中大跌5.12%，巨量解禁压力叠加业绩下滑与板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1166498885","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166498885?lang=zh_cn&edition=full","pubTime":"2026-05-11 09:59","pubTimestamp":1778464757,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大跌5.12%，引起了市场的广泛关注。消息面上，公司将于6月30日迎来约1.928亿股限售股解禁，占总股本的34.16%，相当于当前流通盘翻倍有余，市场对可能出现的集中抛压感到担忧。此外，公司一季度归母净利润环比大幅下降约73%，扣非净利润仍处于亏损状态，基本面压力尚未被市场充分消化。同时，生物科技板块今日整体表现疲软，行业情绪低迷也对个股形成了拖累。综合来看，巨量限售股解禁带来的潜在供给压力、公司短期业绩的大幅下滑以及行业整体的弱势环境，共同导致了荣昌生物股价在盘中的显著下跌。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411573","title":"每周股票复盘：荣昌生物（688331）将召开2025年度暨2026年一季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411573?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:24","pubTimestamp":1778347450,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，荣昌生物报收于123.9元，较上周的129.31元下跌4.18%。本周，荣昌生物5月8日盘中最高价报132.02元。本周关注点公司公告汇总：荣昌生物将于2026年5月14日召开2025年度暨2026年一季度集体业绩说明会。公司公告汇总荣昌生物制药（烟台）股份有限公司将于2026年5月14日下午15:00-16:15通过上证路演中心和第一财经平台，以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064131003.USD","LU1064130708.USD","BK1574","688331","BK1583","LU1969619763.USD","BK1161","LU2488822045.USD","LU2148510915.USD","09995","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633315551","title":"荣昌生物（688331）披露参加‘对话成长’2025年度暨2026年一季度集体业绩说明会公告，5月6日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633315551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633315551?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:05","pubTimestamp":1778076320,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，荣昌生物报收于127.7元，较前一交易日下跌1.25%，最新总市值为720.84亿元。该股当日开盘129.0元，最高130.32元，最低127.5元，成交额达13.71亿元，换手率为6.52%。荣昌生物制药（烟台）股份有限公司近日披露《关于参加“对话成长”2025年度暨2026年一季度集体业绩说明会的公告》。公告显示，公司将于2026年5月14日下午15:00-16:15通过上证路演中心和第一财经平台，以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1161","BK1574","LU1969619763.USD","BK0239","LU2148510915.USD","BK1583","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120732998","title":"荣昌生物2026年4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1120732998","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120732998?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:48","pubTimestamp":1778057301,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年5月6日发布截至2026年4月30日的股份变动月报表。报告期内，公司股本结构保持稳定，未出现新增发行、回购、注销或库存股份变动。H股方面，上月底与本月底已发行股份保持208,581,239股不变。关于股权激励计划，公司在2022年及2023年分别通过相关A股股票激励计划，授出限制性股票，但本月并无新股实际发行或库藏股份转让，股数较上月未发生变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185348739","title":"异动解读 | 荣昌生物盘中大跌6.51%，一季度业绩环比回落及板块情绪低迷成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1185348739","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185348739?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:49","pubTimestamp":1777859379,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中大跌6.51%，引起了市场的广泛关注。消息面上，公司此前披露的一季度业绩显示，其归母净利润虽同比扭亏为盈，但较上一季度环比大幅下降约73%，且扣非净利润仍为亏损。业绩环比大幅回落，叠加该股前期累计较大涨幅，持续引发市场获利了结压力。此外，南向资金此前已连续净减持该股，资金面承压明显。从板块角度看，今日生物科技行业整体表现偏弱，行业情绪低迷进一步拖累了荣昌生物的股价表现。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0509},{"period":"1month","weight":-0.2542},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.0482},{"period":"1year","weight":0.7149},{"period":"ytd","weight":0.1778}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045671},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}